Ascendis Pharma (ASND) PT Raised to $195 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq ease from record highs as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts ASND Hot Sheet
Price: $227.54 +0.66%
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 66
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 66
Join SI Premium – FREE
Wedbush analyst Liana Moussatos raised the price target on Ascendis Pharma (NASDAQ: ASND) to $195.00 (from $164.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
- Sonic Auto (SAH) PT Lowered to $74 at UBS
- Phinia Inc. (PHIN) PT Lowered to $68 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
